Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Pennisi, Angela ^a   Ling, Wen ^a   Li, Xin ^a   Khan, Sharmin ^a   Wang, Yuping ^a   Barlogie, Bart ^a   Shaughnessy Jr , John D ^a   Yaccoby, Shmuel ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; CXCL14 CHEMOKINE; DICKKOPF 1 PROTEIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE RECEPTOR; PLATELET DERIVED GROWTH FACTOR A; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; WNT PROTEIN; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MASS; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; HUMAN; INFLAMMATION; MORPHOMETRICS; MOUSE; MULTIPLE MYELOMA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OXIDATIVE STRESS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; BONE; CYTOLOGY; DISEASE MODEL; METABOLISM; MOUSE MUTANT; PATHOLOGY;

MURINAE; MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, SCID; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOLYSIS; PARATHYROID HORMONE; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 78650875646     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015233     Document Type: Article

References (74)

1. Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, et al. (1991) Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88: 62-66.
2. Roodman GD (2004) Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 32: 290-292.
3. Yaccoby S (2010) Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol 149: 311-321.
4. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, et al. (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580-8587.
5. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, et al. (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7: 377-387.
6. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, et al. (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23: 4925-4935.
7. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, et al. (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108: 3289-3294.
8. Stewart JP, Shaughnessy JD, Jr. (2006) Role of osteoblast suppression in multiple myeloma. J Cell Biochem 98: 1-13.
9. Giuliani N, Rizzoli V, Roodman GD (2006) Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood 108: 3992-3996.
10. Edwards CM, Zhuang J, Mundy GR (2008) The pathogenesis of the bone disease of multiple myeloma. Bone 42: 1007-1013.
11. Yaccoby S (2009) Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma 51: 213-220.
12. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, et al. (2004) Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 64: 2016-2023.
13. Yaccoby S (2005) The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin Cancer Res 11: 7599-7606.
14. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, et al. (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104: 2484- 2491.
15. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, et al. (2006) Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 91: 192-199.
16. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, et al. (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109: 2106-2111.
17. Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, et al. (2008) Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111: 2833-2842.
18. Qiang YW, Shaughnessy JD, Jr., Yaccoby S (2008) Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. Blood 112: 374-382.
19. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R (1993) Anabolic actions of parathyroid hormone on bone. Endocr Rev 14: 690-709.
20. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, et al. (1999) Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104: 439-446.
21. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, et al. (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441.
22. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, et al. (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349: 1216-1226.
23. Jilka RL (2007) Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40: 1434-1446.
24. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S (2005) Wnt Proteins Prevent Apoptosis of Both Uncommitted Osteoblast Progenitors and Differentiated Osteoblasts by {beta}-Catenin-dependent and -independent Signaling Cascades Involving Src/ERK and Phosphatidylinositol 3-Kinase/AKT. J Biol Chem 280: 41342-41351.
25. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, et al. (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146: 4577-4583.
26. Guo J, Liu M, Yang D, Bouxsein ML, Saito H, et al. (2010) Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab 11: 161-171.
27. Keller H, Kneissel M (2005) SOST is a target gene for PTH in bone. Bone 37: 148-158.
28. Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, et al. (2005) Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem 95: 1178-1190.
29. Qin L, Qiu P, Wang L, Li X, Swarthout JT, et al. (2003) Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem 278: 19723-19731.
30. Suzuki A, Ozono K, Kubota T, Kondou H, Tachikawa K, et al. (2008) PTH/ cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells. J Cell Biochem 104: 304-317.
31. Terauchi M, Li JY, Bedi B, Baek KH, Tawfeek H, et al. (2009) T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab 10: 229-240.
32. Wan M, Yang C, Li J, Wu X, Yuan H, et al. (2008) Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev 22: 2968-2979.
33. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494.
34. Yata K, Yaccoby S (2004) The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 18: 1891-1897.
35. Yaccoby S, Barlogie B, Epstein J (1998) Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92: 2908-2913.
36. Yaccoby S, Epstein J (1999) The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 94: 3576-3582.
37. Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, et al. (2002) Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116: 278-290.
38. Li X, Pennisi A, Zhan F, Sawyer JR, Shaughnessy JD, et al. (2007) Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines. Br J Haematol 138: 802-811.
39. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, et al. (2006) The molecular classification of multiple myeloma. Blood 108: 2020-2028.
40. Otsuki T, Yamada O, Kurebayashi J, Sakaguchi H, Yata K, et al. (2001) Expression and in vitro modification of parathyroid hormone-related protein (PTHrP) and PTH/PTHrP-receptor in human myeloma cells. Leuk Lymphoma 41: 397-409.
41. Yamamoto T, Kambe F, Cao X, Lu X, Ishiguro N, et al. (2007) Parathyroid hormone activates phosphoinositide 3-kinase-Akt-Bad cascade in osteoblast-like cells. Bone 40: 354-359.
42. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, et al. (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26: 688-703.
43. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, et al. (2003) Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278: 50259-50272.
44. Potts JT (2005) Parathyroid hormone: past and present. J Endocrinol 187: 311-325.
45. Park H, No AL, Lee JM, Chen L, Lee SY, et al. (2010) PDE4 inhibitor upregulates PTH-induced osteoclast formation via CRE-mediated COX-2 expression in osteoblasts. FEBS Lett 584: 173-180.
46. Swarthout JT, D'Alonzo RC, Selvamurugan N, Partridge NC (2002) Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. Gene 282: 1-17.
47. Onyia JE, Helvering LM, Gelbert L, Wei T, Huang S, et al. (2005) Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J Cell Biochem 95: 403-418.
48. Sims NA (2010) Building bone with a SOST-PTH partnership. J Bone Miner Res 25: 175-177.
49. Yao GQ, Wu JJ, Troiano N, Insogna K (2010) Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. J Bone Miner Metab.
50. Choi HY, Dieckmann M, Herz J, Niemeier A (2009) Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS ONE 4: e7930.
51. Liu Y, Rubin B, Bodine PV, Billiard J (2008) Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. J Cell Biochem 105: 497-502.
52. Almeida M, Han L, Martin-Millan M, O'Brien CA, Manolagas SC (2007) Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem 282: 27298-27305.
53. Ambrogini E, Almeida M, Martin-Millan M, Paik JH, DePinho RA, et al. (2010) FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice. Cell Metab 11: 136-146.
54. Rached MT, Kode A, Xu L, Yoshikawa Y, Paik JH, DePinho RA, et al. (2010) FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts. Cell Metab 11: 147-160.
55. Allan EH, Hausler KD, Wei T, Gooi JH, Quinn JM, et al. (2008) EphrinB2 Regulation by Parathyroid Hormone (PTH) and PTHrP Revealed by Molecular Profiling in Differentiating Osteoblasts. J Bone Miner Res.
56. Pennisi A, Ling W, Li X, Khan S, Shaughnessy JD, Jr., et al. (2009) The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood 114: 1803-1812.
57. Jeong BC, Kim HJ, Bae IH, Lee KN, Lee KY, et al. (2010) COMP-Ang1, a chimeric form of Angiopoietin 1, enhances BMP2-induced osteoblast differentiation and bone formation. Bone 46: 479-486.
58. Sabbieti MG, Agas D, Xiao L, Marchetti L, Coffin JD, et al. (2009) Endogenous FGF-2 is critically important in PTH anabolic effects on bone. J Cell Physiol 219: 143-151.
59. Serra R, Karaplis A, Sohn P (1999) Parathyroid hormone-related peptide (PTHrP)-dependent and -independent effects of transforming growth factor beta (TGF-beta) on endochondral bone formation. J Cell Biol 145: 783-794.
60. Tang Y, Wu X, Lei W, Pang L, Wan C, et al. (2009) TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med 15: 757-765.
61. Graham S, Leonidou A, Lester M, Heliotis M, Mantalaris A, et al. (2009) Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing. Expert Opin Investig Drugs 18: 1633-1654.
62. Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, et al. (2006) A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res 21: 366-373.
63. Bilezikian JP, Matsumoto T, Bellido T, Khosla S, Martin J, et al. (2009) Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res 24: 373-385.
64. Li X, Pennisi A, Yaccoby S (2008) Role of decorin in the antimyeloma effects of osteoblasts. Blood 112: 159-168.
65. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, et al. (2009) Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5: 54-63.
66. Ozawa S, Kato Y, Kubota E, Hata R (2009) BRAK/CXCL14 expression in oral carcinoma cells completely suppresses tumor cell xenografts in SCID mouse. Biomed Res 30: 315-318.
67. Liu S, Tan WY, Chen QR, Chen XP, Fu K, et al. (2008) Daintain/AIF-1 promotes breast cancer proliferation via activation of the NF-kappaB/cyclin D1 pathway and facilitates tumor growth. Cancer Sci 99: 952-957.
68. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC (1998) Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 102: 274-282.
69. Weinstein RS, Jilka RL, Almeida M, Roberson PK, Manolagas SC (2010) Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. Endocrinology 151: 2641-2649.
70. Pennisi A, Li X, Ling W, Khan S, Zangari M, et al. (2009) The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 84: 6-14.
71. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, et al. (2005) Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 131: 71-73.
72. Perrien DS, Akel NS, Edwards PK, Carver AA, Bendre MS, et al. (2007) Inhibin A is an endocrine stimulator of bone mass and strength. Endocrinology 148: 1654-1665.
73. Bendre MS, Gaddy-Kurten D, Mon-Foote T, Akel NS, Skinner RA, et al. (2002) Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 62: 5571-5579.
74. Abe E, Yamamoto M, Taguchi Y, Lecka-Czernik B, O'Brien CA, et al. (2000) Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin. J Bone Miner Res 15: 663-673.